Dupilumab in the management of moderate-to-severe asthma: the data so far.

Barranco, Pilar; Phillips-Angles, Elsa; Dominguez-Ortega, Javier; Quirce, Santiago

Barranco, Pilar; Phillips-Angles, Elsa; Dominguez-Ortega, Javier; Quirce, Santiago.

Afiliación

Barranco P; Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Phillips-Angles E; Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Dominguez-Ortega J; Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Quirce S; Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Ther Clin Risk Manag ; 13: 1139-1149, 2017.

Article en En | MEDLINE | ID: mdl-28979129

Palabras clave

asthma; dupilumab; interleukin-13; interleukin-4; monoclonal antibodies; treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Ther Clin Risk Manag Año: 2017 Tipo del documento: Article País de afiliación: España

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google